Histrelin (Vantas)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: LH-RH agonist. Histrelin acetate inhibits gonadotropin secretion by desensitizing responsiveness of the pituitary gonadotropin which, in turn, causes a reduction in testicular steroidogenesis.[1][2][3]
Route: SC
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

History of changes in FDA indication

  • 2004-10-12: Initial approval in the palliative treatment of advanced prostate cancer. (Based on Schlegel 2006)

History of changes in Health Canada indication

  • 2006-03-10: Initial notice of compliance (unclear details)

Patient drug information

Also known as

  • Generic name: histrelin acetate
  • Brand names: Supprelin, Vantas